Marginal Zone Lymphoma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of marginal zone lymphoma (MZL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of MZL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s MZL forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with MZL per year?
- Of all people diagnosed with MZL, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MZL over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following MZL subpopulations:
- Diagnosed prevalent cases of marginal zone lymphoma.
- Diagnosed drug-treatable cases.
- Diagnosed drug-treated cases.
Note: Coverage may vary by country.
Table of contents
- Marginal Zone Lymphoma - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Incidence of MZL per 100,000 People of All Ages in 2021 and 2041tttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Marginal Zone Lymphoma Over the Next 20 Yearstttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Incident Cases
- Diagnosed Prevalent Cases
- Drug-Treatable and Drug-Treated Populations
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Marginal Zone Lymphoma
- Studies Excluded From the Analysis of Marginal Zone Lymphoma
- Risk / Protective Factors
- Risk / Protective Factors for Marginal Zone Lymphoma
- Bibliography
- Glossary
- Abbreviations
- Literature Review
- Introduction
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.